Premium
Polymorphism 4G/5G in the plasminogen activator inhibitor‐1 (PAI‐1) gene is associated with IgE‐mediated allergic diseases and asthma in the Czech population
Author(s) -
Buč D.,
Izakovičová Hollá L.,
Vácha J.
Publication year - 2002
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1034/j.1398-9995.2002.03582.x
Subject(s) - asthma , immunoglobulin e , plasminogen activator inhibitor 1 , immunology , plasminogen activator , medicine , polymorphism (computer science) , allergic asthma , population , gene polymorphism , allele , gene , biology , genetics , antibody , environmental health
Background: Plasminogen activator inhibitor type 1 (PAI‐1) is a glycoprotein that belongs to the serine protease inhibitor superfamily and has an essential role in tissue remodeling after inflammation. Recently, a single base pair deletion/insertion (4G/5G) polymorphism of the PAI‐1 gene has been associated with an increased risk of asthma in nuclear families from the UK. Methods: The present study was thus conducted to determine the association of this polymorphism with the development of IgE‐mediated asthma and other allergic diseases in the Czech population. A case‐control approach was used in our study. DNA taken from subjects with clinically manifested asthma and other allergic diseases ( n = 207) and from reference ethnically age‐gender‐matched unrelated subjects ( n = 186) was examined for base deletions/insertions in the PAI‐1 gene. Results: A significant association ( P = 0.0035) was observed between the PAI‐1 promoter polymorphism and IgE‐mediated allergic diseases altogether. Furthermore, the 4G allele frequency was also significantly higher in the asthmatic patients than in the control group ( P = 0.0148). Conclusions: Our findings support the idea that the 4G allele of the 4G/5G polymorphism in the PAI‐1 gene may be a risk factor for IgE‐mediated asthma and allergic diseases.